首页> 外文期刊>Mayo Clinic Proceedings >Subclinical hypothyroidism: an update for primary care physicians.
【24h】

Subclinical hypothyroidism: an update for primary care physicians.

机译:亚临床甲状腺功能减退症:基层医疗医生的最新动态。

获取原文
获取原文并翻译 | 示例
           

摘要

Subclinical hypothyroidism (SCH), also called mild thyroid failure, is diagnosed when peripheral thyroid hormone levels are within normal reference laboratory range but serum thyroid-stimulating hormone (TSH) levels are mildly elevated. This condition occurs in 3% to 8% of the general population. It is more common in women than men, and its prevalence increases with age. Of patients with SCH, 80% have a serum TSH of less than 10 mIU/L. The most important implication of SCH is high likelihood of progression to clinical hypothyroidism. The possibility that it is a cardiovascular risk factor has been a subject of debate. Large-scale randomized studies are needed for evidence-based recommendations regarding screening for mild thyroid failure and levothyroxine therapy for this condition. Currently, the practical approach is routine levothyroxine therapy for persons with a persistent serum TSH of more than 10.0 mIU/L and individualized therapy for those with a TSH of less than 10.0 mIU/L.
机译:当外周甲状腺激素水平在正常参考实验室范围内但血清甲状腺刺激激素(TSH)水平轻度升高时,诊断为亚临床甲状腺功能减退症(SCH),也称为轻度甲状腺功能衰竭。这种情况发生在总人口的3%至8%。它在女性中比男性更常见,并且其流行程度随年龄增长而增加。在SCH患者中,有80%的血清TSH低于10 mIU / L。 SCH最重要的含义是发展为临床甲状腺功能减退的可能性很高。它是否是心血管危险因素一直是争论的话题。需要进行大规模的随机研究,以提供关于筛查轻度甲状腺衰竭和左甲状腺素治疗该病的循证医学推荐。目前,实际方法是对血清TSH持续高于10.0 mIU / L的患者进行常规左甲状腺素治疗,对TSH低于10.0 mIU / L的患者进行个体化治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号